StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO Capital Reiterates Outperform on Pfizer (PFE) Following 4Q
February 3, 2016 8:21 AM
BMO Capital maintained an Outperform rating on Pfizer (NYSE: PFE), and cut the price target to $39.00 (from $41.00), following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Pfizer (PFE) CEO Read Sees Doing Smaller Deals Following Closure of Allergan Merger - Conf. Call
February 2, 2016 11:22 AM
Axovant Sciences (AXON) Sell-Off Creates Buying Opportunity - Piper Jaffray
February 2, 2016 11:07 AM
Intercept Pharma (ICPT) on Watch Following Rumors Out of UK
February 2, 2016 9:54 AM
Pfizer 2016 forecast disappoints
February 2, 2016 6:52 AM
Pfizer (PFE) Tops Q4 EPS by 1c
February 2, 2016 6:45 AM
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2015 RESULTS
February 2, 2016 6:45 AM
Trading Radar for 2/2: Yahoo! (YHOO). ExxonMobil (XOM), Ferrari (RACE), Chipotle (CMG), UPS (UPS) Report
February 1, 2016 3:29 PM
Portola Pharma (PTLA) Enters Licensing Agreements for Investigational Agent Andexanet in Japan (BMY) (PFE)
February 1, 2016 6:56 AM
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
February 1, 2016 6:55 AM
